CCR4 and its ligands: from bench to bedside.

Area of Science:

• Immunology
• Cell Biology
• Oncology

Background:

• Chemokines and receptors guide cell movement; humans have 44 chemokines and 23 receptors.
• CC chemokine receptor 4 (CCR4) binds CCL17 and CCL22.
• CCR4 is expressed on Th2, skin-homing T cells, Treg cells, and notably in T-cell neoplasms.

Purpose of the Study:

• To provide an overview of CCR4 and its ligands.
• To highlight the clinical relevance of CCR4 in T-cell subsets and neoplasms.
• To discuss the development of Mogamulizumab, an anti-CCR4 antibody therapy.

Main Methods:

• Review of basic and clinical research on CCR4 and its ligands.
• Analysis of CCR4 expression in T-cell subsets and malignancies.
• Description of Mogamulizumab development and therapeutic application.

Main Results:

• CCR4 plays a crucial role in T-cell migration and homing.
• CCR4 is significantly overexpressed in adult T-cell leukemia/lymphoma (ATL) and cutaneous T-cell lymphomas (CTCLs).
• Mogamulizumab, a defucosylated anti-CCR4 antibody, has been developed for treating relapsed/refractory ATL and CTCLs.

Conclusions:

• CCR4 is a significant therapeutic target for T-cell malignancies.
• Targeting CCR4 with antibodies like Mogamulizumab offers a promising treatment strategy.
• Further research into CCR4 biology may uncover new therapeutic avenues.